Alpha-1: Year 1

An Alpha-1 diagnosis is the first step in a lifelong journey.

Understanding Alpha-1 and what’s next

Now that you’ve been diagnosed, you might be wondering about the effects of Alpha-1 and what’s next. It is natural to have questions. It’s also normal to wonder who will be helping you start your therapy.

The best thing you can do to help educate yourself is speak with an AlphaNet Coordinator to address your questions or concerns.* He or she is a fellow Alpha who can relate to what you may be going through and can explain Alpha-1 and what comes next.

Learn about the many people who will help you start and stay on treatment.

*AlphaNet Coordinators are neither healthcare professionals nor medical experts. Their assistance does not constitute professional guidance, therapy, or psychological counseling. Always contact your physician with medical questions. For their time and expenses, AlphaNet Coordinators are compensated by AlphaNet Inc., an independent, not-for-profit, 501(c)(3) health management organization.

Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated to raise the plasma level of alpha1-proteinase inhibitor (A1-PI) in patients with A1-PI deficiency and related emphysema. The effect of this raised level on the frequency of pulmonary exacerbations and the progression of emphysema have not been established in clinical trials.

Zemaira may not be suitable for everyone; for example, people with known hypersensitivity to components used to make Zemaira, those with a history of anaphylaxis or severe systemic response to A1-PI products, and those with certain IgA deficiencies. If you think any of these may apply to you, ask your doctor.

Early signs of hypersensitivity reactions to Zemaira include hives, rash, tightness of the chest, unusual breathing difficulty, wheezing, and feeling faint. Immediately discontinue use and consult with physician if such symptoms occur.

In clinical studies, the following adverse reactions were reported in at least 5% of subjects receiving Zemaira: headache, sinusitis, upper respiratory infection, bronchitis, fatigue, increased cough, fever, injection-site bleeding, nasal symptoms, sore throat, and swelled blood vessels.

Because Zemaira is made from human blood, the risk of transmitting infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information for Zemaira.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

CSL Behring

Zemaira is manufactured and distributed by CSL Behring LLC.
Zemaira® and CareZ® are registered trademarks of CSL Behring LLC.

© 2017 CSL Behring. The product information presented on this site is intended for US residents only.
ZMR14-04-0006d 12/2014